Lifileucel

3 trials 1 recruiting

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

1 Recruiting

2 Completed trials

1 Sponsors

12 Countries

Phase III

Phase II

Phase III: 1 Phase II: 2

Oversight events:

8 temporary halts 1 unexpected event 1 corrective measure across 1 trial

View oversight register →

Indications tested

Malignant melanoma 1 Squamous cell carcinoma of head and neck 1 Non-small cell lung cancer 1

Sponsors using this IMP

Iovance Biotherapeutics Inc. 3

All trials

3 total

Study to investigate lifileucel regimen plus pembrolizumab compared with pembrolizumab alone in participants with untreated, advanced melano… Recruiting

2022-503140-41-00 Phase III 12 countries Iovance Biotherapeutics Inc.
A clinical study to investigate if the investigational products, called LN-144 and LN-145 (also known as Tumour Infiltrating Lymphocytes), a… Ended

2024-510779-39-00 Phase II 3 countries Iovance Biotherapeutics Inc.
A study of lifileucel (tumor-infiltrating lymphocytes) in adults with advanced melanoma Ended

2025-522054-40-00 Phase II 4 countries Iovance Biotherapeutics Inc.

Showing 1–3 of 3 trials

← All drugs A–Z